iTeos Therapeutics, Inc. (ITOS) has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $10.047 in cash per share of common stock.
Under the terms of the agreement, Concentra will launch a tender offer by August 1, 2025, to purchase all outstanding shares of iTeos common stock for the specified offer consideration.
This transaction involving iTeos Therapeutics, Inc. is expected to close in the third quarter of 2025.
